Dr. Ya-Hsuan Chang

Assistant Investigator


Ph.D., Institute of Biomedical Engineering, National Taiwan University (2009)

M.S., School of Public Health, National Defense Medical Center (2004)

B.S., Department of Nursing, College of Medicine, National Taiwan University (1999)


2023-present Assistant Investigator, Institute of Molecular and Genomic Medicine, National Health Research Institutes
2021-present Adjunct Assistant Research Scientist, Department of Medical Research, Kaohsiung Medical University Chung-Ho Memorial Hospital 
2019- present Postdoctoral Fellow, Institute of Statistical Science, Academia Sinica
2018-2019 Advanced RD Manager, Acer Inc.
2017-2018 Postdoctoral Fellow, Research Center for Genomic Medicine, National Taiwan university
2015-2017 Postdoctoral Fellow, Institute of Statistical Science, Academia Sinica


Computational multi-omics and precision medicine

Through high throughput data including microarray and next generation sequencing data, we have a great chance to reveal complex biological mechanisms contributed to diseases and identify biomarkers to reach precision medicine. Dr. Chang expertise in integrating biological knowledge, epidemiology concepts, informatics and statistics in omics data. Through omics data analysis and cooperating with different domain experts,  the potential causal or predictive factors of the diseases or drug response could be identified. For instance, environmental carcinogen and APOBEC mutational signature are the potential casual factor of the non-smoking lung cancer and biomarker of the immuno-therapy, respectively (Cell, 2020). Besides, Dr. Chang having working experiences in the industry, findings of studies may have chance to translate into the bio-industry.

Immunity assessment system for precision cancer immunotherapy

In the nineteen century, using the immune system as a cancer treatment strategy has been proposed. Nowadays, besides surgery, radiation, and chemotherapy, the immune-based treatment turns into the important approach to treat patients with cancer. Immunotherapy is a way to help immune cells to fight cancers and treatment strategies are including molecular therapy, cellular therapy, and vaccination therapy. However, treatment responses and effects are quite different from each patient and less patients response to the immunotherapy. Immunity affected by complex interactions between tumor, host and microenvironment. It is valuable to establish comprehensive immunity assessment model to stratify patients into different immune status and help them to receive the adequate medical management. Therefore, through integrating omics data, immune information would be available and could be used to develop the immunity assessment system to reach the goal of precision immunotherapy.


Oral presentation award, Year-end retreat, Taiwan Genomics and Genetics Society, 2014

Oral presentation award, Year-end retreat, Taiwan Genomics and Genetics Society, 2012


  1. Wang, T.H., Huang, K.Y., Chen, C.C., Chang, Y.H., Chen, H.Y., Hsueh, C., Liu, Y.T., Yang, S.C., Yang, P.C., and Chen, C.Y. (2023). PM2.5 promotes lung cancer progression through activation of the AhR-TMPRSS2-IL18 pathway. EMBO Mol Med, e17014. (IF: 14.0, 6.0%).
  2. Yu, C.H., Chang, Y.H., Wang, D.S., Jou, S.T., Lin, C.Y., Lin, K.H., Lu, M.Y., Wu, K.H., Cheng, C.N., Chang, H.H., et al. (2023). Allele-specific polymerase chain reaction can determine the diplotype of NUDT15 variants in patients with childhood acute lymphoblastic Leukemia. Sci Rep 13, 490. (IF: 4.99, 25.6%).
  3. Chang, Y. H.#, Jou, S. T.#, Yen, C. T., Lin, C. Y., Yu, C. H., Chang, S. K., Lu, M. Y., Chang, H. H., Pai, C. H., Hu, C. Y., Lin, K. H., Lin, S. R., Lin, D. T., Chen, H. Y., Yang, Y. L.*, Lin, S. W.*, and Yu, S. L.*. A microRNA signature for clinical outcomes of pediatric ALL patients treated with TPOG protocols. Am J Cancer Res 12, 4764-4774 (2022). (IF: 5.9, 29.0%).
  4. Yang, C. Y., Lin, Y. T., Lin, L. J., Chang, Y. H., Chen, H. Y., Wang, Y. P., Shih, J. Y., Yu, C. J., and Yang, P. C.*. Stage Shift Improves Lung Cancer Survival: Real-World Evidence. J Thorac Oncol 1016/j.jtho.2022.09.005 (2022). (IF: 20.1, 5.3%)
  5. Chang, Y. H. #, Yu, C. H. #, Jou, S. T., Lin, C. Y., Lin, K. H., Lu, M. Y., Wu, K. H., Chang, H. H., Lin, D. T., Lin, S. W., Chen, H. Y.*, and Yang, Y. L.*. Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia. Sci Rep 12;11(1):769 (2021). (IF: 5.0, 25.7%)
  6. Lu, C. S., Lin, C. W., Chang, Y. H., Chen, H. Y., Chung, W. C., Lai, W. Y., Ho, C. C., Wang, T. H., Chen, C. Y., Yeh, C. L., Wu, S., Wang, S. P.*, and Yang, P. C.*. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. J Immunother Cancer 8(2) (2020). (IF: 13.8, 4.9%)
  7. Chen, Y. J.#, Roumeliotis, T. I. #, Chang, Y. H. #, Chen, C. T., Han, C. L.*, Lin, M. H., Chen, H. W., Chang, G. C., Chang, Y. L., Wu, C. T., Lin, M. W., Hsieh, M. S., Wang, Y. T., Chen, Y. R., Jonassen, I., Gravidel, F. Z., Lin, Z. S., Lin, K. T., Chen, C. W., Sheu, P. Y., Hung, C. T., Huang, K. C., Yang, H. C., Lin, P. Y., Yen, T. C., Lin, Y. W., Wang, J. H., Raghav, L., Lin, C. Y., Chen, Y. S., Wu, P. S., Lai, C. T., Weng, S. H., Su, K. Y., Chang, W. H., Tsai, P. Y., Robles, A. I., Rodriguez, H., Hsiao, Y. J., Chang, W. H., Sung, T. Y.*, Chen, J. S.*, Yu. S. L.*, Choudhary, J. S.*, Chen, H. Y.*, Yang, P. C.*, and Chen, Y. J.*. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. Cell 182, 226-244 (2020). (*First author; IF:41.6, 0.7%)
  8. Yu, C. H., Chang, Y. H., Wang, D. S., Jou, S. T., Lin, C. Y., Lin, K. H., Lu, M. Y., Raghav, L., Chang, H. H., Wu, K. H., Chou, S. W., Ni, Y. L., Lin., D. T., Lin, S. W., Chen, H. Y., and Yang, Y. L.*. Determination of NUDT15 variants by targeted sequencing can identify compound heterozygosity in pediatric acute lymphoblastic leukemia patients. Sci Rep 10, 14400 (2020). (IF: 4.4, 23.6%)
  9. Wang, D. S., Yu, C. H., Lin, C. Y., Chang, Y. H., Lin, K. H., Lin, D. T., Jou, S. T., Lu, M. Y., Chang, H. H., Lin, S. W., Chen, H. Y., and Yang, Y. L*. Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants. Pediatr Res, doi:10.1038/s41390-020-0868-8 (2020). (IF: 6.2, 15.4%)
  10. Huang, P., Yang, Y. H., Chang, Y. H., Chang, S. L., Chou, M. C., Lai, C. L.*, Liu, C. K.*, and Chen, H. Y.*. Association of early-onset Alzheimer’s disease with germline-generated high affinity self-antigen load. Transl Psychiat 10, 146, doi:10.1038/s41398-020-0826-6 (2020). (IF: 8.0, 15.5%)

Comments are closed.